All In Biotech

Drug Trial Radar · NCT04680598

Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

Comparison of Hepatitis B Virus Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing Immune Checkpoint Inhibitor and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

Last checked: Nov 19, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Dec 25, 2020

Primary completion

Dec 31, 2023

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kaiping Central Hospital; Guangzhou No.12 People's Hospital; ZhongShan People 's Hospital
First posted
Dec 23, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years

Summary

As written by the sponsor on the registry.

Immune checkpoint inhibitor (ICI), including programmed cell death protein-1 (PD-1) inhibitor or programmed cell death-Ligand 1 (PD-L1) inhibitor , is recommended to treat advanced hepatocellular carcinoma (HCC). However, the safety of ICI in patients with a high HBV-DNA load is unknown because of the potential risk of hepatitis B virus (HBV) reactivation. This study was to compare the HBV reactivation between patients with low HBV-DNA loads and high HBV-DNA loads undergoing antiviral prophylaxis and ICI.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • ICIDrug

    Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)

  • Antiviral ProphylaxisDrug

    Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBV Reactivation rateTime frame: 2 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • ZhongShan People 's Hospital

    Zhongshan, China · Recruiting

  • Cancer Center Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Guangzhou Twelfth People 's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Kaiping Central Hospital

    Kaiping, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.